Labcorp Enhances Alzheimer's Testing Portfolio with Latest pTau217 Diagnostic
Wednesday, 20 March 2024, 13:00
Labcorp Expands Alzheimer's Testing Portfolio with pTau217 Test
Labcorp (LH) has introduced the pTau217 test as a new component in its Alzheimer's testing arsenal, focusing on a vital blood-based biomarker of the disease. This latest offering underscores Labcorp's dedication to enhancing diagnostic options for Alzheimer's patients.
Key Highlights:
- LH Introduces pTau217 Test: Labcorp adds the pTau217 test to its Alzheimer's testing portfolio.
- Targeting a Critical Biomarker: The pTau217 test is designed to pinpoint a key blood-based biomarker of Alzheimer's.
- Significance of the Innovation: The introduction of the pTau217 test reflects Labcorp's commitment to advancing diagnostic solutions for Alzheimer's, potentially leading to improved patient outcomes.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.